Tel +49 (0)30 560 42240, Mon - Fri, 9am - 1pm

TA-65® extends telomeres: randomized, double-blind, placebo controlled study in vivo

The latest study confirms the findings on the extension of telomeres in a randomized, double-blind, placebo-controlled study in vivo (human) of TA-65® over a period of one year.
This study was conducted with 117 relatively healthy CMV (cytomegalovirus) positive subjects aged 53 to 87 years.
Patients with low dose (250 units / day) over the 12-month period had a significantly increased telomeric length while patients in the placebo group lost the length of the telomeres.

The results suggest that TA-65 extends in a statistically and possibly clinically significant manner.
Pub Med 3/2016, Engl. (PDF) read here